• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Page 3 > Press

In the media

Page 3 > Press

In the media

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

In the media
8 Jul 2026

No medicine for dengue yet, Serum Institute’s new treatment is headed for global trials

The Print
Viewpoints
3 Aug 2026

A new chapter for African medical innovation

Nature Africa
Daily Nation logo
In the media
1 Aug 2026

End of painful injections as Kenya set to adopt new 14-day Kala-azar treatment

Daily Nation
New Vision logo
In the media
30 Jul 2026

WHO approves new shorter, less painful Kala-azar treatment for East Africa

New Vision
Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
Leishmaniasis patient Monica Lomoler carrying a bunch of firewood
Press releases
29 Jul 2026

WHO recommends new, better and safer treatment regimens for leishmaniasis

Press releases
27 Jul 2026

DNDi leadership to change in 2027

Stories
16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications
16 Jul 2026

DNDi 2025 Annual Report

The Telegraph
In the media
15 Jul 2026

Dengue outbreak complicates Bangladesh measles crisis response

The Telegraph
Laboratory of Medicinal and Computational Chemistry (LQMC), São Paulo University USP, São Carlos Campus, São Paulo Brazil.
Press releases
13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security 

Chepokarial Rubben attentively cares for her five-year-old son, Romanu Kiptoo, at the kala-azar ward of Kacheliba Sub-County Referral Hospital in West Pokot County, Kenya. She gently soothes him, offering comfort as he endures the painful treatment for kala-azar.
Press releases
13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Scientific articles
9 Jul 2026

Consensus framework for developing a target product profile of real-time PCR in Chagas disease therapeutic monitoring

PLOS Neglected Tropical Diseases
The Indian Express logo
In the media
9 Jul 2026

Serum Institute of India ties up with DNDi for Phase III trial of dengue therapy

The Indian Express
Press Releases Translations
8 Jul 2026

Brasil, Malásia e Tailândia estão prestes a iniciar ensaio clínico para testar tratamento promissor contra a dengue desenvolvido pelo Instituto Serum da Índia

Press Releases Translations
8 Jul 2026

Brasil, Malasia y Tailandia están a punto de iniciar ensayos clínicos para probar un prometedor tratamiento contra el dengue desarrollado por el Serum Institute of India

loading
Loading...
El Pais logo
In the media
11 Mar 2026

Tres pastillas para eliminar la enfermedad del sueño en un contexto de recortes globales en ayuda al desarrollo

El País
RFI logo
In the media
10 Mar 2026

Entretien avec Dr Hélène Mahenzi à propos d’un nouveau médicament développé contre la maladie du sommeil

RFI Priorité Santé
El Pais logo
In the media
9 Mar 2026

Falta de medicamentos, centros médicos destruidos y recortes: cómo la guerra en Sudán ha golpeado a las enfermedades más olvidadas

El País
Nature Africa logo
In the media
3 Mar 2026

Single-dose treatment approved for sleeping sickness

Nature Africa
Nature Africa logo
In the media
3 Mar 2026

Traitement à dose unique approuvé pour la maladie du sommeil

Nature Africa
La Razón
In the media
2 Mar 2026

Europa da el visto bueno a una terapia más sencilla contra la enfermedad del sueño

La Razon
Science logo
In the media
27 Feb 2026

‘Truly spectacular’ drug for sleeping sickness simplifies treatment, raising hopes for eradication

Science
France 24 logo
In the media
27 Feb 2026

La maladie du sommeil bientôt éliminée ? Feu vert européen à un nouveau traitement

France 24
Le Monde logo
In the media
27 Feb 2026

Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030

Le Monde
Bloomberg logo
In the media
27 Feb 2026

New pill has potential to eliminate deadly sleeping sickness

Bloomberg
AP logo
In the media
27 Feb 2026

New sleeping sickness pill gets nod, paving the way for use in Africa

Associated Press
KBC logo
In the media
27 Feb 2026

Breakthrough single-dose treatment for sleeping sickness gets EU nod

KBC
In the media
27 Feb 2026

Single-dose sleeping sickness pill clears major EU regulatory milestone

Capital FM
Citizen TV logo
In the media
27 Feb 2026

EMA gives positive opinion for single-dose sleeping sickness medication

Citizen Digital
Fierce Pharma logo, red copy on white background
In the media
27 Feb 2026

After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’

Fierce Pharma
China Philantrophist magazine logo, cp letters in dark red and chinese characters in black
In the media
26 Feb 2026

被忽视疾病的希望

China Philanthropy Magazine
1 2 … 130 ›

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Twitter Facebook Instagram Youtube Linkedin
EN ESPAÑOL
EM PORTUGUÊS
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license